JP5974180B2 - ピラゾール誘導体を含む腎臓疾患の予防または治療用組成物 - Google Patents
ピラゾール誘導体を含む腎臓疾患の予防または治療用組成物 Download PDFInfo
- Publication number
- JP5974180B2 JP5974180B2 JP2015529664A JP2015529664A JP5974180B2 JP 5974180 B2 JP5974180 B2 JP 5974180B2 JP 2015529664 A JP2015529664 A JP 2015529664A JP 2015529664 A JP2015529664 A JP 2015529664A JP 5974180 B2 JP5974180 B2 JP 5974180B2
- Authority
- JP
- Japan
- Prior art keywords
- pyrazol
- pyridin
- propyl
- phenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120093936A KR101633957B1 (ko) | 2012-08-27 | 2012-08-27 | 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 |
| KR10-2012-0093936 | 2012-08-27 | ||
| PCT/KR2013/006985 WO2014035070A1 (ko) | 2012-08-27 | 2013-08-02 | 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531774A JP2015531774A (ja) | 2015-11-05 |
| JP2015531774A5 JP2015531774A5 (enExample) | 2015-12-17 |
| JP5974180B2 true JP5974180B2 (ja) | 2016-08-23 |
Family
ID=50183832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015529664A Active JP5974180B2 (ja) | 2012-08-27 | 2013-08-02 | ピラゾール誘導体を含む腎臓疾患の予防または治療用組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10047067B2 (enExample) |
| EP (1) | EP2889032B1 (enExample) |
| JP (1) | JP5974180B2 (enExample) |
| KR (1) | KR101633957B1 (enExample) |
| CN (1) | CN104755077B (enExample) |
| ES (1) | ES2734264T3 (enExample) |
| PL (1) | PL2889032T3 (enExample) |
| TR (1) | TR201909923T4 (enExample) |
| WO (1) | WO2014035070A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101826208B1 (ko) | 2016-02-05 | 2018-02-06 | 경북대학교 산학협력단 | 뉴로펩타이드 y를 유효성분으로 포함하는, 신장질환의 예방 또는 치료용 약학적 조성물 |
| KR101856444B1 (ko) * | 2017-04-20 | 2018-05-10 | 압타바이오 주식회사 | 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물 |
| KR101840702B1 (ko) * | 2017-11-01 | 2018-03-22 | 압타바이오 주식회사 | 간질환 치료제 |
| CN114746079A (zh) | 2019-11-21 | 2022-07-12 | 三进制药株式会社 | 用于预防或治疗眼部疾病的滴眼剂组合物 |
| KR102277665B1 (ko) * | 2020-02-05 | 2021-07-15 | 바이오그래핀 주식회사 | 그래핀 기반 신장 질환 치료용 조성물 |
| EP4134079A4 (en) * | 2020-04-08 | 2024-04-24 | Aptabio Therapeutics Inc. | AGENT FOR THE TREATMENT OF ACUTE KIDNEY INJURY INDUCED BY CONTRAST PRODUCT |
| KR102308991B1 (ko) * | 2020-04-08 | 2021-10-06 | 압타바이오 주식회사 | 조영제 유발 급성 신부전 치료제 |
| KR102386097B1 (ko) * | 2020-04-13 | 2022-04-14 | 압타바이오 주식회사 | 피라졸 유도체의 폐섬유증 치료제 |
| JP7539485B2 (ja) * | 2020-04-13 | 2024-08-23 | アプタバイオ セラピューティクス インコーポレイテッド | ピラゾール誘導体の肺線維症治療剤 |
| CA3203975A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| KR102589130B1 (ko) | 2021-03-24 | 2023-10-13 | 삼진제약주식회사 | N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물 |
| US12031128B2 (en) | 2021-04-07 | 2024-07-09 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
| CN119504599B (zh) * | 2024-11-18 | 2025-09-26 | 安徽医科大学 | 一种用于治疗肾脏纤维化的吡唑类化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4023488A1 (de) | 1990-07-24 | 1992-01-30 | Bayer Ag | 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide |
| AU2697092A (en) | 1991-10-08 | 1993-05-03 | Nippon Soda Co., Ltd. | Pyrazole derivative and agrohorticultural bactericide containing same |
| JP2003098120A (ja) | 2001-09-26 | 2003-04-03 | Tokyo Weld Co Ltd | 外観検査装置 |
| JP4189850B2 (ja) | 2002-05-20 | 2008-12-03 | 味の素株式会社 | 線維化病変組織修復剤 |
| KR20040094464A (ko) | 2003-05-02 | 2004-11-10 | 학교법인 이화학당 | 피리디닐 피라졸 유도체 |
| JPWO2006129587A1 (ja) | 2005-05-30 | 2009-01-08 | 株式会社ジーンケア研究所 | ピラゾロン誘導体を含有する医薬組成物 |
| ATE550334T1 (de) | 2006-09-01 | 2012-04-15 | Otsuka Agritechno Co Ltd | N-pyridylpiperidinverbindung, verfahren zu ihrer herstellung und schädlingsbekämpfungsmittel |
| KR100942382B1 (ko) | 2008-03-25 | 2010-02-12 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물 |
| US8637674B2 (en) | 2009-09-02 | 2014-01-28 | Ewha University-Industry Collaboration Foundation | Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same |
| KR101280160B1 (ko) * | 2009-09-02 | 2013-06-28 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
-
2012
- 2012-08-27 KR KR1020120093936A patent/KR101633957B1/ko active Active
-
2013
- 2013-08-02 US US14/424,771 patent/US10047067B2/en active Active
- 2013-08-02 PL PL13834243T patent/PL2889032T3/pl unknown
- 2013-08-02 JP JP2015529664A patent/JP5974180B2/ja active Active
- 2013-08-02 EP EP13834243.1A patent/EP2889032B1/en active Active
- 2013-08-02 WO PCT/KR2013/006985 patent/WO2014035070A1/ko not_active Ceased
- 2013-08-02 ES ES13834243T patent/ES2734264T3/es active Active
- 2013-08-02 CN CN201380056244.5A patent/CN104755077B/zh active Active
- 2013-08-02 TR TR2019/09923T patent/TR201909923T4/tr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140027833A (ko) | 2014-03-07 |
| TR201909923T4 (tr) | 2019-07-22 |
| US20150218125A1 (en) | 2015-08-06 |
| KR101633957B1 (ko) | 2016-06-27 |
| EP2889032A4 (en) | 2016-03-09 |
| WO2014035070A1 (ko) | 2014-03-06 |
| CN104755077B (zh) | 2018-05-15 |
| CN104755077A (zh) | 2015-07-01 |
| JP2015531774A (ja) | 2015-11-05 |
| EP2889032B1 (en) | 2019-05-08 |
| US10047067B2 (en) | 2018-08-14 |
| PL2889032T3 (pl) | 2019-09-30 |
| EP2889032A1 (en) | 2015-07-01 |
| ES2734264T3 (es) | 2019-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5974180B2 (ja) | ピラゾール誘導体を含む腎臓疾患の予防または治療用組成物 | |
| JP6812564B2 (ja) | 肝疾患治療剤 | |
| JP7628591B2 (ja) | 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物およびその用途 | |
| KR101630432B1 (ko) | 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물 | |
| JP6635527B2 (ja) | 高尿酸血症又は痛風の治療又は予防用化合物 | |
| KR101302315B1 (ko) | 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물 | |
| KR20180086497A (ko) | sGC 자극제를 포함하는 고체 분산물 | |
| JP2023511302A (ja) | 新規なピラゾール誘導体 | |
| EP2682392A2 (en) | Pyrazole derivatives, preparation method thereof, and composition for preventing and treating osteoporosis containing same | |
| KR20220152549A (ko) | 약제로서 유용한 적어도 하나의 카복시기, 설포기 또는 아미도기를 갖는 2,5- 또는 2,6-이치환된 하이드로퀴논 유도체 | |
| WO2002006249A1 (en) | Method for producing 1-substituted-1,2,3-triazole derivative | |
| CN113527153A (zh) | 一类抑制肠道炎症反应的活性化合物 | |
| KR101683362B1 (ko) | 소양증 개선 활성을 갖는 벤즈옥사졸 유도체 | |
| CN112079744B (zh) | 芳香酰腙衍生物及其作为na抑制剂的应用 | |
| RU2846904C1 (ru) | Новое производное пиразола | |
| RU2846904C9 (ru) | Новое производное пиразола | |
| US20250387375A1 (en) | Sofalcone derivatives and medical use thereof | |
| CN106032378B (zh) | 新型arb化合物及其用途 | |
| CN106536519A (zh) | 唑苯衍生物的晶体 | |
| CN118084898A (zh) | iCRT14衍生物及其制备方法和应用 | |
| CN104072501B (zh) | 一种治疗阴道炎的化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150424 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20150810 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150810 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150917 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160425 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160628 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160715 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5974180 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |